Pharma Companies Hit with Two Price-Fixing Lawsuits
by Erin Shaak
Last Updated on May 8, 2018
Louisiana Health Service Indemnity Company v. Actavis Holdco U.S., Inc. et al
Filed: April 25, 2017 ◆§ 2:17-cv-01877-CMR
Two Louisiana insurance companies have jointly filed two different lawsuits against pharmaceutical companies for allegedly conspiring to fix the prices of generic drugs.
Two Louisiana insurance companies have jointly filed two different lawsuits against pharmaceutical companies for allegedly conspiring to fix the prices of generic drugs.
The first suit claims nine drug manufacturers raised the price of generic pravastatin between 300 and 600 percent over a period of 8 months. The plaintiffs’ customers are dependent on this drug, which is used to treat high cholesterol and triglycerides, and are forced to pay whatever price the defendants ask, according to the complaint.
The second suit has been filed against four pharmaceutical companies and two individual officers of one of the companies. It claims that the defendants conspired to fix the price of generic glyburide, which is used to treat type 2 diabetes. According to the complaint, the individual defendants have pled guilty in a recent lawsuit over similar allegations.
The plaintiffs argue that the defendants’ anticompetitive behavior has artificially inflated the cost of medicine on which thousands of consumers depend, and has forced them to pay unreasonably high prices for the drugs, to the manufacturers’ benefit.
Hair Relaxer Lawsuits
Women who developed ovarian or uterine cancer after using hair relaxers such as Dark & Lovely and Motions may now have an opportunity to take legal action.
Read more here: Hair Relaxer Cancer Lawsuits
How Do I Join a Class Action Lawsuit?
Did you know there's usually nothing you need to do to join, sign up for, or add your name to new class action lawsuits when they're initially filed?
Read more here: How Do I Join a Class Action Lawsuit?
Stay Current
Sign Up For
Our Newsletter
New cases and investigations, settlement deadlines, and news straight to your inbox.
Before commenting, please review our comment policy.